A phase II study of temsirolimus added to low-dose weekly carboplatin and paclitaxel for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)

BACKGROUND: Activating events along the PI3K/mTOR pathway are common in head and neck squamous cell carcinomas (HNSCC), and preclinical studies suggest additive or synergistic effects when combining mTORC1 inhibitors with carboplatin and paclitaxel chemotherapy. PATIENTS AND METHODS: In this single-...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Ann Oncol
Main Authors: Dunn, L. A., Fury, M. G., Xiao, H., Baxi, S. S., Sherman, E. J., Korte, S., Pfister, C., Haque, S., Katabi, N., Ho, A. L., Pfister, D. G.
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2017
Teme:
Original Articles
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5834071/
https://ncbi.nlm.nih.gov/pubmed/28961834
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdx346
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki